Purpose of this Study
We are doing this study learn more about circulating immune cells and circulating tumor cells (CTCs) in patients with metastatic renal cell carcinoma or metastatic urothelial carcinoma.
We are also looking at the bacteria in your gut and urinary tract to learn about how these bacteria affect how your cancer responds to immunotherapy.
We are also looking at the bacteria in your gut and urinary tract to learn about how these bacteria affect how your cancer responds to immunotherapy.
Who Can Participate?
Eligibility
Adult patients with renal or bladder cancer who are planning to start an immunotherapy.
What is Involved?
If you choose to join this study, there will be four different timepoints.
At these timepoints, we will:<ul>
<li>Collect blood, urine and stool samples</li>
<li>Review your chart to find out how your body is reacting to the immunotherapy and how your cancer is responding to the immunotherapy</li></ul>
At these timepoints, we will:<ul>
<li>Collect blood, urine and stool samples</li>
<li>Review your chart to find out how your body is reacting to the immunotherapy and how your cancer is responding to the immunotherapy</li></ul>
Study Details
Full Title
Exploring relevant immune-based biomarkers and circulating tumor cells during treatment with immune checkpoint inhibitors in genitourinary malignancies
Principal Investigator
Shahla
Bari
Protocol Number
PRO00076768
NCT ID
NCT02978118
Phase
N/A
Enrollment Status
Open to Enrollment